Start Publications Lactosylated Glycogen Nanoparticles for Targeting Prostate ...
QSense

Lactosylated Glycogen Nanoparticles for Targeting Prostate Cancer Cells

Year: 2017

Journal: ACS Appl. Mater. Interfaces, Volume 9, MAY 24, page 16870–16880

Authors: Besford, Quinn A.; Wojnilowicz, Marcin; Suma, Tomoya; Bertleff-Zieschang, Nadja; Caruso, Frank; Cayalieri, Francesca

Keywords: glycogen; nanoparticle; prostate cancer; lectins; targeting; beta-galactoside

Glyconanoparticles that exhibit multivalent binding to lectins are desirable for molecular recognition and therapeutic applications. Herein we explore the use of glycogen nanoparticles as a biosourced glycoscaffold for engineering multivalent glyconanoparticles. Glycogen nano particles, a naturally occurring highly branched polymer of glucose, was functionalized with lactose, achieved through copper(I)-catalyzed alkyne-azide cycloaddition chemistry, for targeted interaction with lectins ex situ and on prostate cancer cells. The lactosylated glycogen, which contains terminal beta-galactoside moieties, is termed galacto-glycogen (GG), and is found to interact strongly with peanut agglutinin (PNA), a beta-galactoside specific lectin, as observed by optical waveguide lightmode spectroscopy, dynamic light scattering, and quartz crystal microbalance measurements. The GG nanoparticles exhibit multivalent binding to PNA with an affinity constant of 3.4 x 10(5) M-1 and the GG PNA complex cannot he displaced by lactose, demonstrating the competitive binding of GG to the lectin. These GG nanoparticles were tested for association with prostate cancer cell membranes in vitro, where the particles exhibited a high affinity for the membrane, as observed from flow cytometry and confocal microscopy. This is inferred to result from specific extracellular galectin-1 targeting. Furthermore, the GG nanoparticles induce aggregation between prostate cancer cells. Our results highlight a strategy for engineering a biosourced polysaccharide with surface moieties that exhibit strong multivalent interactions with lectins, and targeted interaction with prostate cancer cells.